$GHST
GHST World Inc.

2024 Q3 Form 10-K Financial Statement

#000107997324001394 Filed on October 11, 2024

View on sec.gov

Income Statement

Concept 2024 Q3 2024 Q2 2024
Revenue $45.73K $40.92K
YoY Change 91.82% 1229.3%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin
YoY Change
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $58.45K $551.9K
YoY Change -25.86% 362.12%
Operating Profit
YoY Change
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net $0.00 -$317.00
YoY Change -100.0% 39.65%
Pretax Income
YoY Change
Income Tax
% Of Pretax Income
Net Earnings -$12.72K -$511.3K
YoY Change -77.33% 338.59%
Net Earnings / Revenue -27.81% -1249.59%
Basic Earnings Per Share $0.00 $0.00
Diluted Earnings Per Share $0.00 $0.00
COMMON SHARES
Basic Shares Outstanding 130.2M shares 130.2M shares 129.1M shares
Diluted Shares Outstanding 130.2M shares 129.1M shares

Balance Sheet

Concept 2024 Q3 2024 Q2 2024
SHORT-TERM ASSETS
Cash & Short-Term Investments
YoY Change
Cash & Equivalents $2.168K $18.30K
Short-Term Investments
Other Short-Term Assets
YoY Change
Inventory
Prepaid Expenses
Receivables $0.00 $3.749K
Other Receivables
Total Short-Term Assets $2.168K $22.05K
YoY Change -87.98% -44.17%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $0.00 $0.00
YoY Change
TOTAL ASSETS
Total Short-Term Assets $2.168K $22.05K
Total Long-Term Assets $0.00 $0.00
Total Assets $2.168K $22.05K
YoY Change -87.98% -44.17%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable
YoY Change
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $323.2K $330.3K
YoY Change 65.18% 105.16%
LONG-TERM LIABILITIES
Long-Term Debt
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $323.2K $330.3K
Total Long-Term Liabilities
Total Liabilities
YoY Change
SHAREHOLDERS EQUITY
Retained Earnings -$13.89M -$13.88M
YoY Change 3.48% 3.82%
Common Stock $130.2K $130.2K
YoY Change 3.56% 3.56%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$321.0K -$308.3K
YoY Change
Total Liabilities & Shareholders Equity $2.168K $22.05K
YoY Change -87.98% -44.17%

Cashflow Statement

Concept 2024 Q3 2024 Q2 2024
OPERATING ACTIVITIES
Net Income -$12.72K -$511.3K
YoY Change -77.33% 338.59%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$45.17K -$164.6K
YoY Change 4.32% 76.35%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $0.00
YoY Change -100.0%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities $29.04K $143.4K
YoY Change 158.29% 8.12%
NET CHANGE
Cash From Operating Activities -$45.17K -$164.6K
Cash From Investing Activities
Cash From Financing Activities $29.04K $143.4K
Net Change In Cash -$16.13K -$21.19K
YoY Change -49.67% -153.94%
FREE CASH FLOW
Cash From Operating Activities -$45.17K -$164.6K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2024 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
CY2024 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2024 dei Entity Central Index Key
EntityCentralIndexKey
0001121795
CY2024Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2023Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2024 dei Document Type
DocumentType
10-K
CY2024 dei Document Annual Report
DocumentAnnualReport
true
CY2024 dei Document Period End Date
DocumentPeriodEndDate
2024-06-30
CY2024 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--06-30
CY2024 dei Document Transition Report
DocumentTransitionReport
false
CY2024 dei Entity File Number
EntityFileNumber
000-31705
CY2024 dei Entity Registrant Name
EntityRegistrantName
GHST World Inc.
CY2024 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2024 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
91-2007477
CY2024 dei Entity Address Address Line1
EntityAddressAddressLine1
667 Madison Avenue
CY2024 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2024 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2024 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2024 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2024 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2024 dei Entity Small Business
EntitySmallBusiness
true
CY2024 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2024 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2024 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2024 dei Document Fin Stmt Error Correction Flag
DocumentFinStmtErrorCorrectionFlag
false
CY2024 dei Entity Shell Company
EntityShellCompany
false
CY2023Q4 dei Entity Public Float
EntityPublicFloat
3407776 usd
CY2024Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
130201179 shares
CY2024 dei Auditor Firm
AuditorFirmId
5525
CY2024 dei Auditor Name
AuditorName
Fruci & Associates II, PLLC
CY2024 dei Auditor Location
AuditorLocation
Spokane, WA
CY2023 dei Auditor Name
AuditorName
Salberg
CY2023 dei Auditor Firm
AuditorFirmId
106
CY2023 dei Auditor Location
AuditorLocation
Boca Raton, Florida
CY2024Q2 us-gaap Cash
Cash
18302 usd
CY2023Q2 us-gaap Cash
Cash
39495 usd
CY2024Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
3749 usd
CY2023Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
0 usd
CY2024Q2 us-gaap Assets Current
AssetsCurrent
22051 usd
CY2023Q2 us-gaap Assets Current
AssetsCurrent
39495 usd
CY2024Q2 us-gaap Assets
Assets
22051 usd
CY2023Q2 us-gaap Assets
Assets
39495 usd
CY2024Q2 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
13814 usd
CY2023Q2 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
1112 usd
CY2024Q2 GHST Due To Related Party Current
DueToRelatedPartyCurrent
269854 usd
CY2023Q2 GHST Due To Related Party Current
DueToRelatedPartyCurrent
126496 usd
CY2024Q2 GHST Common Stock Payable
CommonStockPayable
9559 usd
CY2023Q2 GHST Common Stock Payable
CommonStockPayable
9559 usd
CY2024Q2 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
37098 usd
CY2023Q2 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
23841 usd
CY2024Q2 us-gaap Liabilities Current
LiabilitiesCurrent
330325 usd
CY2023Q2 us-gaap Liabilities Current
LiabilitiesCurrent
161008 usd
CY2024Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2024Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2023Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2024Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000 shares
CY2023Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000 shares
CY2024Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
130201179 shares
CY2023Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
125725003 shares
CY2024Q2 us-gaap Common Stock Value
CommonStockValue
130201 usd
CY2023Q2 us-gaap Common Stock Value
CommonStockValue
125725 usd
CY2024Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
13443466 usd
CY2023Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
13123419 usd
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-13881949 usd
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-13370665 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
-308274 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-121513 usd
CY2024Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
22051 usd
CY2023Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
39495 usd
CY2024 us-gaap Revenues
Revenues
40916 usd
CY2023 us-gaap Revenues
Revenues
3078 usd
CY2024 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
540069 usd
CY2023 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
114622 usd
CY2024 GHST Patent Development Costs
PatentDevelopmentCosts
11814 usd
CY2023 GHST Patent Development Costs
PatentDevelopmentCosts
4803 usd
CY2024 us-gaap Operating Expenses
OperatingExpenses
551883 usd
CY2023 us-gaap Operating Expenses
OperatingExpenses
119425 usd
CY2024 us-gaap Other Income
OtherIncome
-317 usd
CY2023 us-gaap Other Income
OtherIncome
-227 usd
CY2024 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-317 usd
CY2023 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-227 usd
CY2024 us-gaap Net Income Loss
NetIncomeLoss
-511284 usd
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-116574 usd
CY2024 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.00
CY2023 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.00
CY2024 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.00
CY2023 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.00
CY2024 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
129051560 shares
CY2023 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
125042819 shares
CY2024 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
129051560 shares
CY2023 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
125042819 shares
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
-101006 usd
CY2023 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
96067 usd
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-116574 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-121513 usd
CY2024 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
324523 usd
CY2024 us-gaap Net Income Loss
NetIncomeLoss
-511284 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
-308274 usd
CY2024 us-gaap Net Income Loss
NetIncomeLoss
-511284 usd
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-116574 usd
CY2024 us-gaap Share Based Compensation
ShareBasedCompensation
324523 usd
CY2023 us-gaap Share Based Compensation
ShareBasedCompensation
0 usd
CY2024 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
3749 usd
CY2023 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-0 usd
CY2024 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
12702 usd
CY2023 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-574 usd
CY2024 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
13257 usd
CY2023 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
23841 usd
CY2024 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-164551 usd
CY2023 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-93307 usd
CY2024 us-gaap Proceeds From Repayments Of Related Party Debt
ProceedsFromRepaymentsOfRelatedPartyDebt
143358 usd
CY2023 us-gaap Proceeds From Repayments Of Related Party Debt
ProceedsFromRepaymentsOfRelatedPartyDebt
36529 usd
CY2024 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0 usd
CY2023 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
96067 usd
CY2024 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
143358 usd
CY2023 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
132596 usd
CY2024 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-21193 usd
CY2023 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
39289 usd
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
39495 usd
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
206 usd
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
18302 usd
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
39495 usd
CY2024 us-gaap Interest Paid Net
InterestPaidNet
0 usd
CY2023 us-gaap Interest Paid Net
InterestPaidNet
0 usd
CY2024 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0 usd
CY2023 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0 usd
CY2024 us-gaap Net Income Loss
NetIncomeLoss
-511284 usd
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-116574 usd
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-13881949 usd
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-13370665 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
-308274 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-121513 usd
CY2024 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-164551 usd
CY2023 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-93307 usd
CY2024 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p id="xdx_84B_eus-gaap--ConcentrationRiskCreditRisk_zILE7T88dR49" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="xdx_863_zOfsPTjOHu66">Concentration</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company’s financial instruments that are exposed to concentrations of credit risk primarily consist of its cash. The Company places its cash with financial institutions of high credit worthiness. At times, its cash with a particular financial institution may exceed any applicable government insurance limits. The Company’s management plans to assess the financial strength and credit worthiness of any parties to which it is a credit counterparty, and as such, it believes that any associated credit risk exposures are limited.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company currently receives nearly all its revenues from two customers and all the deferred revenues from a few other customers. The Company is dependent on its chairman of the Board for short term funding, who has provided a significant portion of the funding through June 30, 2024.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
CY2024 us-gaap Use Of Estimates
UseOfEstimates
<p id="xdx_845_eus-gaap--UseOfEstimates_zH74yCCaqUdc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="xdx_86D_zFRz98DA2ag6">Use of Estimates</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Such estimates and assumptions impact, among others, the following: fair value of share-based payments and deferred taxes.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ significantly from estimates.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
CY2024Q2 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
0 usd
CY2023Q2 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
0 usd
CY2024Q2 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
0 usd
CY2023Q2 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
0 usd
CY2024 us-gaap Fair Value Asset Liability Recurring Basis Still Held Unrealized Gain Loss
FairValueAssetLiabilityRecurringBasisStillHeldUnrealizedGainLoss
0 usd
CY2023 us-gaap Fair Value Asset Liability Recurring Basis Still Held Unrealized Gain Loss
FairValueAssetLiabilityRecurringBasisStillHeldUnrealizedGainLoss
0 usd
CY2024 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
0 shares
CY2023 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
0 shares
CY2021Q3 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
1-for-100
CY2024Q2 GHST Common Stock Payable
CommonStockPayable
9559 usd
CY2023Q2 GHST Common Stock Payable
CommonStockPayable
9559 usd
CY2024Q2 GHST Due To Related Party Current And Noncurrent
DueToRelatedPartyCurrentAndNoncurrent
269854 usd
CY2023Q2 GHST Due To Related Party Current And Noncurrent
DueToRelatedPartyCurrentAndNoncurrent
126496 usd
CY2024Q2 GHST Common Stock Payable Related Parties
CommonStockPayableRelatedParties
9559 usd
CY2024Q2 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0 usd
CY2023Q2 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0 usd
CY2024 us-gaap Operating Loss Carryforwards Limitations On Use
OperatingLossCarryforwardsLimitationsOnUse
The Company has accumulated losses of approximately $13.8 million since its inception. For income tax purposes, the Company has operating loss carryforwards of approximately $3.6 million from tax years beginning in 2007, that begin to expire in 2027.
CY2024Q2 us-gaap Operating Loss Carryforwards Valuation Allowance
OperatingLossCarryforwardsValuationAllowance
913000 usd
CY2024 GHST Effective Combined Federal And State Tax Rate
EffectiveCombinedFederalAndStateTaxRate
0.2535 pure
CY2024 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.2100 pure
CY2023 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210 pure
CY2024 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.0550 pure
CY2023 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.0550 pure
CY2024 us-gaap Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential
EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
-0.0115 pure
CY2023 us-gaap Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential
EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
-0.0115 pure
CY2024 GHST Effective Combined Federal And State Tax Rate
EffectiveCombinedFederalAndStateTaxRate
0.2535 pure
CY2023 GHST Effective Combined Federal And State Tax Rate
EffectiveCombinedFederalAndStateTaxRate
0.2535 pure
CY2024 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.2535 pure
CY2023 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.2535 pure
CY2024 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
0.0000 pure
CY2023 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
0.0000 pure
CY2024Q2 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q2 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q2 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q2 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0001079973-24-001394-index-headers.html Edgar Link pending
0001079973-24-001394-index.html Edgar Link pending
0001079973-24-001394.txt Edgar Link pending
0001079973-24-001394-xbrl.zip Edgar Link pending
ex21x1.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
ghst-20240630.xsd Edgar Link pending
ghst_10k.htm Edgar Link pending
ghst_ex31z1a.htm Edgar Link pending
ghst_ex31z1b.htm Edgar Link pending
ghst_ex31z1c.htm Edgar Link pending
ghst_ex32z1.htm Edgar Link pending
image_003.jpg Edgar Link pending
image_004.jpg Edgar Link pending
image_005.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
ghst-20240630_cal.xml Edgar Link unprocessable
ghst-20240630_def.xml Edgar Link unprocessable
ghst-20240630_lab.xml Edgar Link unprocessable
ghst-20240630_pre.xml Edgar Link unprocessable
ghst_10k_htm.xml Edgar Link completed